mardi 13 septembre 2022

U.S : Insulin prices are TOO HIGH.

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
Congress passed the Inflation Reduction Act, which places a $35 cap on insulin for people 65 and over and on Medicare patients. But millions of diabetics on private insurance will still pay substantially more for insulin – in many cases, more than they can easily afford.

Uninsured people have it the worst. Despite being much less likely to be able to afford prescription medicines, they are far more likely to pay the full list price for insulin than the privately insured.

Republican senators voted against the cap on the price of insulin in the private market, removing it from the package, once again caving to pressures from Big Pharma at the expense of American citizens.

About 14% of diabetics in the U.S., nearly 1.2 million people, spend at least 40% of their income (outside of food and housing costs) on insulin. Many are forced to ration their doses, or simply cannot afford insulin at all, all because we refuse to rein in Big Pharma. Under- or unmedicated diabetes can be deadly.
 
 
 
 
 
American families are struggling. What Big Pharma is doing is not just unethical, it is life-threatening. We must have access to affordable medication. Congress must step in and cap insulin prices for all immediately, regardless of insurance status.
 
 
 
 
 
Thanks for all you do,
 
 
 
 

Erin Tulley
, Daily Kos.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Daily Kos Relies on Readers Like You.
We don't have billionaire backers like some right-wing media outlets. Half our revenue comes from readers like you, meaning we literally couldn't do this work without you. Can you chip in $5 right now to help Daily Kos keep fighting ?
Chip in $5
  Daily Kos, PO Box 70036, Oakland, CA, 94612. Contributions to Daily Kos are not tax deductible.    

Aucun commentaire:

Enregistrer un commentaire